Page 1

PRESS RELEASE Lyon , April 21 , 2021 ADOCIA Announces First Quarter 2021 Financial Results ADOCIA innovative medicine for everyone , everywhere 7:30 am CEST - Adocia ( Euronext Paris : FR0011184241 - ADOC ) , a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides , announced today its first quarter revenue and net cash position on March 31 , 2021 . Revenue detail for the first quarter of 2021 In ( € ) thousands , IFRS standards ( unaudited ) Licensing revenues Research and collaborative agreements REVENUE 03/31/2021 ( 3 months ) 03/31/2020 ( 3 months ) 115 453 115 453 - Revenue was primarily due to the licensing agreements signed with Tonghua Dongbao ( THDB ) in 2018 , to develop , manufacture , and commercialize BioChaperone® Lispro and BioChaperoneⓇ Combo in China and other territories in Asia and the Middle East . - In the first three months of 2021 , revenue was recognized upon provision of research and development services performed by Adocia and related to the transfer and development of the products to THDB . Net cash position The Company had a cash position of EUR 20,3 million as of March 31 , 2021 , compared to EUR 28,1 million as of December 31 , 2020. Cash consumption for the first three months of 2021 was EUR 7,8 million similar to the same period last year ( EUR 8 million ) . As of March 31 , 2021 , financial debt was to EUR 28,5 million compared to EUR 28.2 million as of December 31 , 2020. Debt mainly comprised a financing line consisting in a bond issue for a total of EUR 15 million by IPF Partners in 2019 , a State - guaranteed loan for EUR 7 million obtained in August 2020 , and finally a loan secured in 2016 to finance the acquisition and renovation of the building in which the headquarters and the research center of the Company are located . 1/3